Loading...
By Kristin J. Kelley
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM
Two drugs used to treat type 2 diabetes — canagliflozin and dapagliflozin — are associated with an increased risk for acute kidney injury, cautions the FDA. The language on the existing labels for both sodium-glucose cotransporter-2 (SGLT2) inhibitors will be revised to include more information on this risk and ways to minimize it.
There have been 101 "confirmable" cases of acute kidney injury reported to the FDA from March 2013 to October 2015. Hospitalization was required in 96 cases; 4 patients died. Additionally, 15 required dialysis.
Patients taking canagliflozin and dapagliflozin should be advised to seek medical attention if they notice symptoms of acute kidney injury (e.g., decreased urine, swelling in the legs or feet). The FDA also advises clinicians to evaluate renal function before treatment starts, and then continue to monitor it periodically.
In recent weeks, the agency announced it is investigating a possibly increased amputation risk for patients on canagliflozin. Additionally, late last year, all SGLT2-inhibitor labels were updated to warn of risks for ketoacidosis and serious urinary tract infections.
Comment
LINK(S):
FDA MedWatch safety alert (Free)
Background: Physician's First Watch coverage of new labels for SGLT2 inhibitors warning of UTI and ketoacidosis risk (Free)